Last reviewed · How we verify
NCT03672708
Confocal Laser Endomicroscopy With Cresyl Violet for in Vivo Diagnosis of Gastric Intestinal Metaplasia
NA trial testing Cresyl violet in Gastric Intestinal Metaplasia in 48 participants. Completed in 2 January 2019.
26 October 2018
Quick facts
| Lead sponsor | Shandong University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 48 |
| Start date | 16 September 2018 |
| Primary completion | 26 October 2018 |
| Estimated completion | 2 January 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cresyl violet
Conditions studied
- Gastric Intestinal Metaplasia — all drugs for Gastric Intestinal Metaplasia →
Sponsor
Shandong University
Who can join
18 and older, any sex, with Gastric Intestinal Metaplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Confocal laser endomicroscopy (CLE) is a novel endoscopic system which can provide approximately 1000-fold magnification of the gastrointestinal mucosa. Previous studies have demonstrated its diagnostic value for Gastric intestinal metaplasia (GIM) with the use of a contrast agent.Recently, Cresyl violet (CV) has been used in CLE to visualize tissue architecture in human ileum, colon or myenteric plexus.No investigation has reported the characterization of GIM imaged with CLE when using CV as staining dye
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03672708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Intestinal Metaplasia
Currently open trials in the same condition.
- NCT06590454 — REVerse Intestinal Metaplasia in the Stomach (REVISE) · Phase 2 · recruiting
- NCT06610266 — Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia · Phase 4 · recruiting
- NCT06610760 — Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia · Phase 4 · recruiting
- NCT06370143 — A Study Collecting Health Information to Understand and Prevent Gastric Cancer · recruiting
- NCT05657080 — Cytosponge for Gastric Intestinal Metaplasia · recruiting
Other Shandong University trials
Trials by the same sponsor.
- NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
- NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
- NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
- NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
- NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03672708 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong University
- Last refreshed: 14 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03672708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing